Novo Nordisk A/S Investors Notified of Class Action Securities Lawsuit

Strategic Insights -

Investors in Novo Nordisk A/S ("Novo") have been notified of a class action securities lawsuit, which seeks to recover losses on behalf of investors who were allegedly affected by securities fraud between May 7, 2025 and July 28, 2025. The lawsuit claims that Novo's management made false and misleading statements about the company's growth potential, overstating the impact of personalization exceptions to the compounded GLP-1 exclusion and the likelihood of patients switching to Novo's branded alternatives. On July 29, 2025, Novo announced a lower sales and profit outlook, attributing the guide down to "lowered growth expectations" due to competition and slower-than-expected market expansion. As a result, Novo's stock price declined by 21.83% in a single day.

Key Takeaways:

  • The class action lawsuit alleges that Novo's management made false and misleading statements about the company's growth potential between May 7, 2025 and July 28, 2025.
  • Novo's stock price declined by 21.83% on July 29, 2025, after the company announced a lower sales and profit outlook.
  • The lawsuit claims that Novo's management overstated the impact of personalization exceptions to the compounded GLP-1 exclusion and the likelihood of patients switching to Novo's branded alternatives.
  • The complaint alleges that Novo's management made these false statements to conceal material adverse facts concerning the company's true growth potential.
  • Lead plaintiff status will be determined by the Court, and investors have until September 30, 2025 to request to be appointed lead plaintiff.
  • There is no cost or obligation to participate in the lawsuit, and investors may be entitled to compensation without payment of any out-of-pocket costs or fees.

Statistics:

  • 21.83% decline in Novo's stock price on July 29, 2025, following the announcement of a lower sales and profit outlook.
  • May 7, 2025 to July 28, 2025: the time frame during which Novo's management allegedly made false and misleading statements about the company's growth potential.
  • 70 employees: the number of team members at Levi & Korsinsky, LLP, the law firm representing investors in the class action lawsuit.

Sources:

  • GLOBE NEWSWIRE, "Levi & Korsinsky, LLP Notifies Investors of Class Action Lawsuit Against Novo Nordisk A/S (NVO)", August 05, 2025.
  • ISS Securities Class Action Services, "2025 Top 50 Report".